BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Active, not recruiting · NCT05156710 · Registry updated 2026-08-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) | transplant rejection | Active, not recruiting | Phase 2 | 2026-08-21 | NCT05156710 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sanofi | 254 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham & Women's Hospital- Site Number : 8400004 | Boston | United States | 1 |
| Cedars-Sinai Medical Center- Site Number : 8400100 | Los Angeles | United States | 1 |
| Massachusetts General Hospital- Site Number : 8400007 | Boston | United States | 1 |
| NYU Langone Medical Center- Site Number : 8400102 | New York | United States | 1 |
| University of California Los Angeles Medical Center- Site Number : 8400103 | Los Angeles | United States | 1 |
| University of California San Francisco - Parnassus Heights- Site Number : 8400001 | San Francisco | United States | 1 |
| University of Wisconsin Hospitals and Clinics- Site Number : 8400003 | Madison | United States | 1 |